サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1467742

筋萎縮性側索硬化症治療市場レポート：ALSタイプ、薬剤タイプ、診断タイプ、治療法、流通チャネル、地域別、2024～2032年

Amyotrophic Lateral Sclerosis Treatment Market Report by ALS Type, Drug Type, Diagnosis Type, Treatment, Distribution Channel, and Region 2024-2032

出版日
発行
IMARC
ページ情報
英文 137 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
筋萎縮性側索硬化症治療市場レポート：ALSタイプ、薬剤タイプ、診断タイプ、治療法、流通チャネル、地域別、2024～2032年
出版日: 2024年04月08日
発行: IMARC
ページ情報: 英文 137 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

筋萎縮性側索硬化症治療の世界市場規模は2023年に7億5,440万米ドルに達しました。今後、IMARC Groupは、市場は2032年までに11億1,250万米ドルに達し、2024～2032年の間に4.32%の成長率（CAGR）を示すと予測しています。

筋萎縮性側索硬化症（ALS）治療は、脊髄と脳の神経細胞に影響を及ぼし、筋肉を制御できなくなる変性疾患を指します。それは主に遺伝子の突然変異、無秩序な免疫反応、化学的不均衡などのために発生します。ALSの一般的な症状としては、筋肉のこわばり、筋肉のひきつり、脚や腕の脱力、認知や行動の変化、嚥下障害、ろれつが回らないなどがあります。ALSの診断は、病歴、身体診察、電気診断学的試験、神経画像診断による。

筋萎縮性側索硬化症治療の市場動向：

ライフスタイルの変化や個人の多忙なスケジュールによる神経変性疾患の発生率の上昇が、筋萎縮性側索硬化症治療市場を牽引しています。これに加えて、このような神経疾患に罹患しやすい高齢者人口の拡大も、市場の成長を増大させています。さらに、NGOや民間団体がALSの診断や治療に関する認識を広めるために様々な取り組みを行っています。このことは、市場にとって明るい展望をもたらしています。さらに、ALSの標的治療や対症療法が浸透しつつあることも、市場の成長を促す要因となっています。さらに、臨床試験への注目の高まりとALS治療用経口薬の迅速な承認も市場の成長を後押ししています。さらに、筋機能の強化、免疫調節、神経保護を目的とした革新的な治療法を開発するための様々な研究機関との戦略的共同研究が増加していることも、世界市場をさらに活性化しています。今後数年間、改修政策の浸透とともに医療インフラの継続的なアップグレードが、世界の筋萎縮性側索硬化症治療市場を牽引し続けると考えられます。

本レポートで扱う主要質問

  • 2023年の筋萎縮性側索硬化症治療の世界市場規模は？
  • 2024～2032年の筋萎縮性側索硬化症治療世界市場の予想成長率は？
  • 筋萎縮性側索硬化症治療の世界市場を牽引する主要因は？
  • COVID-19が世界の筋萎縮性側索硬化症治療市場に与えた影響は？
  • 治療法別の筋萎縮性側索硬化症治療の世界市場の内訳は？
  • 筋萎縮性側索硬化症治療世界市場の流通チャネル別区分は？
  • 筋萎縮性側索硬化症治療の世界市場における主要地域は？
  • 筋萎縮性側索硬化症治療の世界市場における主要参入企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 筋萎縮性側索硬化症治療の世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：ALSタイプ別

  • 散発性
  • 家族性

第7章 市場内訳：薬剤タイプ別

  • 市販薬
  • 新興医薬品

第8章 市場内訳：診断タイプ別

  • 筋電図
  • MRI
  • 血液・尿試験
  • 脊髄穿刺
  • 筋生検

第9章 市場内訳：治療法別

  • 薬剤療法
  • 幹細胞治療
  • その他

第10章 市場内訳：流通チャネル別

  • 病院薬局
  • 小売薬局
  • その他

第11章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第12章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第13章 バリューチェーン分析

第14章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第15章 価格分析

第16章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • AB Science
    • Ascend Pharmaceuticals LLC
    • BrainStorm Cell Therapeutics Inc.
    • Corestem Inc.
    • Cytokinetics Inc.
    • Eledon Pharmaceuticals Inc.
    • Ionis Pharmaceuticals Inc.
    • ITF Pharma（Italfarmaco S.p.A）
    • Mitsubishi Chemical Group Corpotion
    • Revalesio Corporation
    • Treeway B.V.
図表

List of Figures

  • Figure 1: Global: Amyotrophic Lateral Sclerosis Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million US$), 2018-2023
  • Figure 3: Global: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 4: Global: Amyotrophic Lateral Sclerosis Treatment Market: Breakup by ALS Type (in %), 2023
  • Figure 5: Global: Amyotrophic Lateral Sclerosis Treatment Market: Breakup by Drug Type (in %), 2023
  • Figure 6: Global: Amyotrophic Lateral Sclerosis Treatment Market: Breakup by Diagnosis Type (in %), 2023
  • Figure 7: Global: Amyotrophic Lateral Sclerosis Treatment Market: Breakup by Treatment (in %), 2023
  • Figure 8: Global: Amyotrophic Lateral Sclerosis Treatment Market: Breakup by Distribution Channel (in %), 2023
  • Figure 9: Global: Amyotrophic Lateral Sclerosis Treatment Market: Breakup by Region (in %), 2023
  • Figure 10: Global: Amyotrophic Lateral Sclerosis Treatment (Sporadic ALS) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Amyotrophic Lateral Sclerosis Treatment (Sporadic ALS) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Amyotrophic Lateral Sclerosis Treatment (Familial ALS) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Amyotrophic Lateral Sclerosis Treatment (Familial ALS) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Amyotrophic Lateral Sclerosis Treatment (Marketed Drugs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Amyotrophic Lateral Sclerosis Treatment (Marketed Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Amyotrophic Lateral Sclerosis Treatment (Emerging Drugs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Amyotrophic Lateral Sclerosis Treatment (Emerging Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Amyotrophic Lateral Sclerosis Treatment (Electromyogram) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Amyotrophic Lateral Sclerosis Treatment (Electromyogram) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Amyotrophic Lateral Sclerosis Treatment (MRI) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Amyotrophic Lateral Sclerosis Treatment (MRI) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Amyotrophic Lateral Sclerosis Treatment (Blood and Urine Tests) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Amyotrophic Lateral Sclerosis Treatment (Blood and Urine Tests) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Amyotrophic Lateral Sclerosis Treatment (Spinal Tap) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Amyotrophic Lateral Sclerosis Treatment (Spinal Tap) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Amyotrophic Lateral Sclerosis Treatment (Muscle Biopsy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Amyotrophic Lateral Sclerosis Treatment (Muscle Biopsy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Amyotrophic Lateral Sclerosis Treatment (Medication) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Amyotrophic Lateral Sclerosis Treatment (Medication) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Global: Amyotrophic Lateral Sclerosis Treatment (Stem Cell Therapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Global: Amyotrophic Lateral Sclerosis Treatment (Stem Cell Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Global: Amyotrophic Lateral Sclerosis Treatment (Other Treatments) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Global: Amyotrophic Lateral Sclerosis Treatment (Other Treatments) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Global: Amyotrophic Lateral Sclerosis Treatment (Hospital Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Global: Amyotrophic Lateral Sclerosis Treatment (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Global: Amyotrophic Lateral Sclerosis Treatment (Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Global: Amyotrophic Lateral Sclerosis Treatment (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Global: Amyotrophic Lateral Sclerosis Treatment (Other Distribution Channels) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Global: Amyotrophic Lateral Sclerosis Treatment (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: North America: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: North America: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: United States: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: United States: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Canada: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Canada: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Asia-Pacific: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Asia-Pacific: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: China: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: China: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Japan: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Japan: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: India: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: India: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: South Korea: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: South Korea: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Australia: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Australia: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Indonesia: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Indonesia: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Others: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Others: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Europe: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Europe: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Germany: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Germany: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: France: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: France: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: United Kingdom: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: United Kingdom: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Italy: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Italy: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Spain: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Spain: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Russia: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Russia: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Others: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Others: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: Latin America: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 79: Latin America: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 80: Brazil: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 81: Brazil: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 82: Mexico: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 83: Mexico: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 84: Others: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 85: Others: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 86: Middle East and Africa: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 87: Middle East and Africa: Amyotrophic Lateral Sclerosis Treatment Market: Breakup by Country (in %), 2023
  • Figure 88: Middle East and Africa: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 89: Global: Amyotrophic Lateral Sclerosis Treatment Industry: SWOT Analysis
  • Figure 90: Global: Amyotrophic Lateral Sclerosis Treatment Industry: Value Chain Analysis
  • Figure 91: Global: Amyotrophic Lateral Sclerosis Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Amyotrophic Lateral Sclerosis Treatment Market: Key Industry Highlights, 2023 & 2032
  • Table 2: Global: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Breakup by ALS Type (in Million US$), 2024-2032
  • Table 3: Global: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Breakup by Drug Type (in Million US$), 2024-2032
  • Table 4: Global: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Breakup by Diagnosis Type (in Million US$), 2024-2032
  • Table 5: Global: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Breakup by Treatment (in Million US$), 2024-2032
  • Table 6: Global: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 7: Global: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 8: Global: Amyotrophic Lateral Sclerosis Treatment Market: Competitive Structure
  • Table 9: Global: Amyotrophic Lateral Sclerosis Treatment Market: Key Players
目次
Product Code: SR112024A6057

The global amyotrophic lateral sclerosis treatment market size reached US$ 754.4 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 1,112.5 Million by 2032, exhibiting a growth rate (CAGR) of 4.32% during 2024-2032.

Amyotrophic Lateral Sclerosis (ALS) Treatment refers to a degenerative disease that affects the nerve cells in the spinal cord and brain, resulting in loss of muscle control. It primarily occurs due to gene mutation, disorganized immune response, chemical imbalance, etc. Some of the common symptoms of ALS include muscle stiffness, twitching of the muscles, weakness in the legs or arms, cognitive and behavioral changes, trouble in swallowing, slurred speech, etc. The diagnosis of ALS relies on medical history, physical examination, electrodiagnostic testing, and neuroimaging.

Amyotrophic Lateral Sclerosis Treatment Market Trends:

The rising incidences of neurodegenerative disorders due to changing lifestyle patterns and hectic schedules of the individuals are primarily driving the Amyotrophic Lateral Sclerosis Treatment treatment market. Besides this, the expanding geriatric population, who are more susceptible to such neurological ailments, is also augmenting the market growth. Furthermore, several NGOs and private organizations are undertaking numerous initiatives to increase awareness regarding the diagnosis and treatment of ALS among the masses. This, in turn, is creating a positive outlook for the market. Additionally, the growing penetration of targeted and symptomatic treatment options for ALS is acting as a significant growth-inducing factor. Moreover, the elevating focus on clinical trials and faster approval of oral drugs for ALS treatment is also bolstering the market growth. Moreover, the increasing strategic collaborations among various research institutes to develop innovative treatment procedures that aim at enhancing muscle function, immune modulation, and neuroprotection are further catalyzing the global market. In the coming years, the continuous upgradation of healthcare infrastructures along with elevating penetration of refurbishment policies will continue to drive the global amyotrophic lateral sclerosis (ALS) treatment market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global amyotrophic lateral sclerosis treatment market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on ALS type, drug type, diagnosis type, treatment and distribution channel.

Breakup by ALS Type:

Sporadic ALS

Familial ALS

Breakup by Drug Type:

Marketed Drugs

Emerging Drugs

Breakup by Diagnosis Type:

Electromyogram

MRI

Blood and Urine Tests

Spinal Tap

Muscle Biopsy

Breakup by Treatment:

Medication

Stem Cell Therapy

Others

Breakup by Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being AB Science, Ascend Pharmaceuticals LLC, BrainStorm Cell Therapeutics Inc., Corestem Inc., Cytokinetics Inc., Eledon Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., ITF Pharma (Italfarmaco S.p.A), Mitsubishi Chemical Group Corpotion, Revalesio Corporation and Treeway B.V.

Key Questions Answered in This Report

  • 1. What was the size of the global amyotrophic lateral sclerosis treatment market in 2023?
  • 2. What is the expected growth rate of the global amyotrophic lateral sclerosis treatment market during 2024-2032?
  • 3. What are the key factors driving the global amyotrophic lateral sclerosis treatment market?
  • 4. What has been the impact of COVID-19 on the global amyotrophic lateral sclerosis treatment market?
  • 5. What is the breakup of the global amyotrophic lateral sclerosis treatment market based on the treatment?
  • 6. What is the breakup of the global amyotrophic lateral sclerosis treatment market based on the distribution channel?
  • 7. What are the key regions in the global amyotrophic lateral sclerosis treatment market?
  • 8. Who are the key players/companies in the global amyotrophic lateral sclerosis treatment market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Amyotrophic Lateral Sclerosis Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by ALS Type

  • 6.1 Sporadic ALS
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Familial ALS
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Drug Type

  • 7.1 Marketed Drugs
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Emerging Drugs
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Diagnosis Type

  • 8.1 Electromyogram
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 MRI
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Blood and Urine Tests
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Spinal Tap
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Muscle Biopsy
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Market Breakup by Treatment

  • 9.1 Medication
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Stem Cell Therapy
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Distribution Channel

  • 10.1 Hospital Pharmacies
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Retail Pharmacies
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Others
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast

11 Market Breakup by Region

  • 11.1 North America
    • 11.1.1 United States
      • 11.1.1.1 Market Trends
      • 11.1.1.2 Market Forecast
    • 11.1.2 Canada
      • 11.1.2.1 Market Trends
      • 11.1.2.2 Market Forecast
  • 11.2 Asia-Pacific
    • 11.2.1 China
      • 11.2.1.1 Market Trends
      • 11.2.1.2 Market Forecast
    • 11.2.2 Japan
      • 11.2.2.1 Market Trends
      • 11.2.2.2 Market Forecast
    • 11.2.3 India
      • 11.2.3.1 Market Trends
      • 11.2.3.2 Market Forecast
    • 11.2.4 South Korea
      • 11.2.4.1 Market Trends
      • 11.2.4.2 Market Forecast
    • 11.2.5 Australia
      • 11.2.5.1 Market Trends
      • 11.2.5.2 Market Forecast
    • 11.2.6 Indonesia
      • 11.2.6.1 Market Trends
      • 11.2.6.2 Market Forecast
    • 11.2.7 Others
      • 11.2.7.1 Market Trends
      • 11.2.7.2 Market Forecast
  • 11.3 Europe
    • 11.3.1 Germany
      • 11.3.1.1 Market Trends
      • 11.3.1.2 Market Forecast
    • 11.3.2 France
      • 11.3.2.1 Market Trends
      • 11.3.2.2 Market Forecast
    • 11.3.3 United Kingdom
      • 11.3.3.1 Market Trends
      • 11.3.3.2 Market Forecast
    • 11.3.4 Italy
      • 11.3.4.1 Market Trends
      • 11.3.4.2 Market Forecast
    • 11.3.5 Spain
      • 11.3.5.1 Market Trends
      • 11.3.5.2 Market Forecast
    • 11.3.6 Russia
      • 11.3.6.1 Market Trends
      • 11.3.6.2 Market Forecast
    • 11.3.7 Others
      • 11.3.7.1 Market Trends
      • 11.3.7.2 Market Forecast
  • 11.4 Latin America
    • 11.4.1 Brazil
      • 11.4.1.1 Market Trends
      • 11.4.1.2 Market Forecast
    • 11.4.2 Mexico
      • 11.4.2.1 Market Trends
      • 11.4.2.2 Market Forecast
    • 11.4.3 Others
      • 11.4.3.1 Market Trends
      • 11.4.3.2 Market Forecast
  • 11.5 Middle East and Africa
    • 11.5.1 Market Trends
    • 11.5.2 Market Breakup by Country
    • 11.5.3 Market Forecast

12 SWOT Analysis

  • 12.1 Overview
  • 12.2 Strengths
  • 12.3 Weaknesses
  • 12.4 Opportunities
  • 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

  • 14.1 Overview
  • 14.2 Bargaining Power of Buyers
  • 14.3 Bargaining Power of Suppliers
  • 14.4 Degree of Competition
  • 14.5 Threat of New Entrants
  • 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

  • 16.1 Market Structure
  • 16.2 Key Players
  • 16.3 Profiles of Key Players
    • 16.3.1 AB Science
      • 16.3.1.1 Company Overview
      • 16.3.1.2 Product Portfolio
      • 16.3.1.3 Financials
      • 16.3.1.4 SWOT Analysis
    • 16.3.2 Ascend Pharmaceuticals LLC
      • 16.3.2.1 Company Overview
      • 16.3.2.2 Product Portfolio
    • 16.3.3 BrainStorm Cell Therapeutics Inc.
      • 16.3.3.1 Company Overview
      • 16.3.3.2 Product Portfolio
    • 16.3.4 Corestem Inc.
      • 16.3.4.1 Company Overview
      • 16.3.4.2 Product Portfolio
      • 16.3.4.3 Financials
    • 16.3.5 Cytokinetics Inc.
      • 16.3.5.1 Company Overview
      • 16.3.5.2 Product Portfolio
      • 16.3.5.3 Financials
      • 16.3.5.4 SWOT Analysis
    • 16.3.6 Eledon Pharmaceuticals Inc.
      • 16.3.6.1 Company Overview
      • 16.3.6.2 Product Portfolio
      • 16.3.6.3 Financials
    • 16.3.7 Ionis Pharmaceuticals Inc.
      • 16.3.7.1 Company Overview
      • 16.3.7.2 Product Portfolio
      • 16.3.7.3 Financials
      • 16.3.7.4 SWOT Analysis
    • 16.3.8 ITF Pharma (Italfarmaco S.p.A)
      • 16.3.8.1 Company Overview
      • 16.3.8.2 Product Portfolio
    • 16.3.9 Mitsubishi Chemical Group Corpotion
      • 16.3.9.1 Company Overview
      • 16.3.9.2 Product Portfolio
      • 16.3.9.3 Financials
      • 16.3.9.4 SWOT Analysis
    • 16.3.10 Revalesio Corporation
      • 16.3.10.1 Company Overview
      • 16.3.10.2 Product Portfolio
    • 16.3.11 Treeway B.V.
      • 16.3.11.1 Company Overview
      • 16.3.11.2 Product Portfolio